Indoor dining will return to New York City on Valentine’s Day at 25% capacity, New York Gov. Andrew Cuomo said Friday.

Indoor dining was shut down in New York City in December.

On March 15, in-person weddings can resume in New York at 50% capacity, or up to 150 people, he said.

Meanwhile, in hard-hit Los Angeles County, outdoor dining is now allowed to reopen at 50% capacity, but with a restriction: TVs must remain off.

Dr. Jay Butler, deputy director for infectious diseases at the Centers for Disease Control and Prevention, said Friday the U.S. has seen a decline in the last two weeks of new cases and hospitalizations, which is “encouraging." But, he added, "The numbers nationally are still high."

"The pandemic is not yet over yet," Butler told the Infectious Diseases Society of America. "By the time we end our 45 minutes together, roughly 100 more Americans will have died of COVID-19."

Butler stressed that the vaccines are safe and effective and that mild side effects are normal.

"The available data tells us that more than half of people have reported some degree of tiredness and pain at the injection site, although most are able to continue normal daily activities," Butler said. "Many also report symptoms such as headache, muscle pain or chills after getting their shots, particularly in the first couple of days. These data also suggest that it may be more common among younger persons after the second dose, but again, this is expected based on some of the data that were available from the clinical trials."

ABC News’ Sophie Tatum contributed to this report.

AstraZeneca’s vaccine on Friday was recommended for conditional marketing authorization in the European Union for people 18 and older. The vaccine is given as two doses.

This is the third vaccine, following Pfizer and Moderna, to be approved by the European Medicines Agency. The AstraZeneca vaccine now awaits final say from the European Commission.

In another promising development for vaccine science, Johnson & Johnson announced Friday that its COVID-19 vaccine -- a single shot tested against a complex barrage of newly emerged variants of the virus -- is 66% effective at preventing symptomatic disease and 85% effective against preventing severe illness.

The U.S. pharmaceutical giant said the vaccine is also safe to take. Volunteers experienced mild reactions after the shot, with less than 10% experiencing fever, according to a company press release.

The full data package will be made publicly available and will be evaluated by the FDA's advisory committee sometime in mid- to late February.

The Food and Drug Administration has said it will consider a vaccine that's more than 50% effective, and the Johnson & Johnson vaccine exceeds this threshold. An emergency use authorization could be given and people could start receiving shots before the end of February.

ABC News' Sony Salzman contributed to this report.

Dr. Anthony Fauci, chief medical adviser to U.S. President Joe Biden and the nation's leading infectious disease expert, said Americans can expect to see more COVID-19 vaccine doses available throughout the country in the coming weeks.

"As we get into February, March and April, we're going to see an escalation of availability of doses that we may have not had a week or two or three ago," Fauci, who is also the director of the National Institute of Allergy and Infectious Diseases, told ABC News chief anchor George Stephanopoulos Thursday on "Good Morning America."

Although COVID-19 data is starting to show some promising trends, Fauci said the U.S. outbreak is "still a very serious situation."

"If you look throughout the country, the dynamics of the outbreak are a little bit unstable," he noted, "even though for the most part we're seeing general trends, seven-day trends of cases going down and ultimately, hopefully, hospitalizations and deaths."

When asked about reopening schools safely, Fauci said COVID-19 transmission rates in schools actually appear to be less than in communities when the schools have the resources and protection they need.

"So if you have a situation where you have dynamics of a viral spread in a community, it's less likely that the children who are in the school -- if we do things right, it's less likely that they're going to get infected," he said. "Obviously we want to get the teachers vaccinated, we want to make sure they have the resources to do it correctly. But when you look at the history of how this virus is moving in schools, it seems to be less spreading there than it is in the community."

Fauci also expressed concern over the new, more contagious variant of the novel coronavirus that was first identified in South Africa and has since spread to dozens of other nations, including the United States.

"The one in South Africa, George, troubles me," he said, explaining that lab experiments show the neutralizing antibodies induced by existing COVID-19 vaccines are "diminished by multifold" when tested against the South Africa variant, called B1351.

"It's still within the range of what you would predict to be protective," he added, "but I take no great comfort in that."

However, scientists are already working on vaccines that will specifically target the South Africa strain, according to Fauci.

"May not be necessary," he said, "but if it is we'll already be on the road to be able to give people a boost that directs against the South African isolate."